Use of 99mTc-HMPAO in Evaluating the Results of Cerebral Hypoperfusion Prevention in the Patients with Coronary Heart Disease after Coronary Artery Bypass Grafting

Abstract

The purpose of this study is to research the use of the radiopharmaceutical99mTc-HMPAO in the evaluation of drug prevention of cerebral complications in patients with coronary heart disease after coronary artery bypass grafting (CABG) performed with cardiopulmonary bypass (CPB). The study included 30 patients, in whom surgical revascularization was performed with CPB. 11 patients in this group were prescribed instenon. All the patients underwent brain tomoscintigraphy with99mTc-HMPAO and neuropsychological testing before CABG and 10-15 days after it. The results showed that99mTc-HMPAO is useful radiopharmaceutical for evaluation of cerebral complications in patients after CABG. Thus, coronary artery bypass grafting using CPB can be complicated by the deterioration of cerebral perfusion and cognitive dysfunction, while preventive medication with instenon can prevent or significantly reduce the violations of cerebral hemodynamics and neuropsychological status of the patients.